Financials Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
22.19 ^CNY	-1.33%		-6.53%	+1.09%

Apr. 30	National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma	CI
Apr. 28	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	23,001	15,174	14,379	8,945	8,945	9,043	-	-
Enterprise Value (EV) ¹	23,001	15,174	14,379	8,945	8,945	9,043	9,043	9,043
P/E ratio	1,087 x	489 x	653 x	511 x	101 x	-56.9 x	-117 x	740 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	132 x	56.3 x	33.4 x	16.9 x	17.1 x	12.8 x	9.64 x	7.39 x
EV / Revenue	132 x	56.3 x	33.4 x	16.9 x	17.1 x	12.8 x	9.64 x	7.39 x
EV / EBITDA	847 x	311 x	383 x	158 x	63.4 x	-100 x	283 x	63.2 x
EV / FCF	-	-	-	-25.1 x	-23.2 x	-51.4 x	-27.1 x	-27.6 x
FCF Yield	-	-	-	-3.99%	-4.31%	-1.95%	-3.69%	-3.63%
Price to Book	15.9 x	10.2 x	10.1 x	6.49 x	5.69 x	5.93 x	6.27 x	6.22 x
Nbr of stocks (in thousands)	410,000	410,000	410,721	406,971	407,537	407,537	-	-
Reference price ²	56.10	37.01	35.01	21.98	21.95	22.19	22.19	22.19
Announcement Date	2/27/20	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	173.8	269.5	430.4	529.9	523.7	705	938	1,224
EBITDA ¹	27.16	48.78	37.54	56.64	141	-90	32	143
EBIT ¹	21.67	36.98	22.26	15.97	97.07	-156	-58	34
Operating Margin	12.47%	13.72%	5.17%	3.01%	18.54%	-22.13%	-6.18%	2.78%
Earnings before Tax (EBT) ¹	20.73	36.17	18.6	15.16	97.02	-160	-80	13
Net income ¹	19.42	31.05	21.96	17.48	88.84	-160	-80	11
Net margin	11.17%	11.52%	5.1%	3.3%	16.96%	-22.7%	-8.53%	0.9%
EPS ²	0.0516	0.0757	0.0536	0.0430	0.2176	-0.3900	-0.1900	0.0300
Free Cash Flow ¹	-	-	-	-356.6	-385.9	-176	-334	-328
FCF margin	-	-	-	-67.29%	-73.68%	-24.96%	-35.61%	-26.8%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	2/27/20	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-357	-386	-176	-334	-328
ROE (net income / shareholders' equity)	2.41%	2.12%	0.02%	1.19%	5.47%	-5.5%	-1.7%	0.8%
ROA (Net income/ Total Assets)	1.15%	-	-	0.72%	2.91%	-4.6%	-1.9%	0.2%
Assets ¹	1,691	-	-	2,414	3,050	3,478	4,211	5,500
Book Value Per Share ²	3.530	3.640	3.450	3.390	3.860	3.740	3.540	3.570
Cash Flow per Share ²	-0.0600	0.2300	0.3000	0.1100	-0.3800	0.1200	0.1900	0.3500
Capex ¹	133	336	288	400	229	199	394	435
Capex / Sales	76.54%	124.79%	67.01%	75.46%	43.65%	28.23%	42%	35.54%
Announcement Date	2/27/20	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.19 CNY

Average target price

31.64 CNY

Spread / Average Target

+42.59%

	1st Jan change	Capi.
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.	+1.09%	1.25B
MERCK KGAA	+15.27%	78.22B
KYOWA KIRIN CO. LTD.	+8.25%	8.84B
SK BIOPHARMACEUTICALS CO., LTD.	-12.05%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+53.66%	4.82B
YUHAN CORPORATION	+11.63%	4.2B
BETTA PHARMACEUTICALS CO., LTD.	-23.67%	2.28B
INDIVIOR PLC	+10.43%	2.28B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-32.35%	2.12B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+21.04%	2.2B